| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 256 | 2020 |
| Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives A Pellino, E Riello, F Nappo, S Brignola, S Murgioni, SA Djaballah, ... World journal of gastroenterology 25 (38), 5773, 2019 | 87 | 2019 |
| Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases F Loupakis, S Sharma, M Derouazi, S Murgioni, P Biason, MD Rizzato, ... JCO Precision Oncology 5, 1166-1177, 2021 | 85 | 2021 |
| Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine–DNA methyltransferase–silenced metastatic … F Morano, A Raimondi, F Pagani, S Lonardi, L Salvatore, C Cremolini, ... Journal of Clinical Oncology 40 (14), 1562, 2022 | 63 | 2022 |
| Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program C Cremolini, D Rossini, E Martinelli, F Pietrantonio, S Lonardi, S Noventa, ... The Oncologist 23 (10), 1178-1187, 2018 | 57 | 2018 |
| Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas A Pellino, S Brignola, E Riello, M Niero, S Murgioni, M Guido, F Nappo, ... Journal of Personalized Medicine 11 (11), 1095, 2021 | 55 | 2021 |
| Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations C Neuzillet, AC Gardini, B Brieau, C Vivaldi, C Smolenschi, G Brandi, ... European Journal of Cancer 111, 94-106, 2019 | 44 | 2019 |
| INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI … F Pietrantonio, A Raimondi, S Lonardi, S Murgioni, GG Cardellino, ... Journal of Clinical Oncology 41 (4_suppl), 358-358, 2023 | 43 | 2023 |
| Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS … D Rossini, C Antoniotti, S Lonardi, F Pietrantonio, R Moretto, L Antonuzzo, ... Journal of Clinical Oncology 40 (25), 2878, 2022 | 36 | 2022 |
| Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first-and second-line treatment of unresectable mCRC. C Cremolini, C Antoniotti, S Lonardi, D Rossini, F Pietrantonio, SS Cordio, ... Journal of Clinical Oncology 37 (15_suppl), 3508-3508, 2019 | 36 | 2019 |
| Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer M Suenaga, M Schirripa, S Cao, W Zhang, D Yang, S Murgioni, D Rossini, ... Annals of Oncology 28 (5), 1015-1022, 2017 | 31 | 2017 |
| Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for … C Cremolini, F Marmorino, F Bergamo, G Aprile, L Salvatore, G Masi, ... European Journal of Cancer 109, 175-182, 2019 | 30 | 2019 |
| Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status F Loupakis, G Maddalena, I Depetris, S Murgioni, F Bergamo, AP Dei Tos, ... Journal for ImmunoTherapy of Cancer 7, 1-7, 2019 | 29 | 2019 |
| Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials S Galdy, CA Cella, F Spada, S Murgioni, AM Frezza, SP Ravenda, ... Critical reviews in oncology/hematology 99, 1-12, 2016 | 29 | 2016 |
| Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside CA Cella, S Minucci, F Spada, S Galdy, M Elgendy, PS Ravenda, ... Cancer Treatment Reviews 41 (9), 754-760, 2015 | 26 | 2015 |
| Capecitabine and temozolomide versus FOLFIRI in RAS-mutated, MGMT-methylated metastatic colorectal cancer F Pietrantonio, R Lobefaro, M Antista, S Lonardi, A Raimondi, F Morano, ... Clinical Cancer Research 26 (5), 1017-1024, 2020 | 25 | 2020 |
| Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer C Neuzillet, A Casadei‐Gardini, B Brieau, C Vivaldi, G Brandi, ... International Journal of Cancer 147 (11), 3177-3188, 2020 | 19 | 2020 |
| 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced … F Pietrantonio, F Morano, S Lonardi, A Raimondi, L Salvatore, ... Annals of Oncology 32, S530-S531, 2021 | 18 | 2021 |
| Prognostic value of thyroid hormone ratios in patients with advanced metastatic colorectal cancer treated with regorafenib: the TOREADOR study M Schirripa, G Pasqualetti, R Giampieri, M Scartozzi, S Lonardi, ... Clinical colorectal cancer 17 (3), e601-e615, 2018 | 15 | 2018 |
| TRIBE2: a phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (PTS) C Cremolini, C Antoniotti, S Lonardi, D Rossini, F Pietrantonio, SS Cordio, ... Annals of Oncology 29, viii715, 2018 | 13 | 2018 |
